New In Vitro Eicosapentaenoic Acid Study Data Presented June 6 at the American Diabetes Association Scientific Sessions in Boston
Get Alerts AMRN Hot Sheet
Join SI Premium – FREE
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/08/15 -- Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts.
The poster, titled "Eicosapentaenoic Acid (EPA) Reduces Glucose-induced Small Dense Low-Density Lipoprotein Oxidation In Vitro in a Manner Distinct from Other Triglyceride-Lowering Agents and Vitamin E," presents data that shows exposure to eicosapentaenoic acid (EPA), an omega-3 fatty acid, inhibited glucose-induced oxidation of small dense LDL. This study examined the effects of EPA and other triglyceride-lowering agents on human sdLDL oxidation following exposure in vitro to hyperglycemic conditions. Exposure to hyperglycemic conditions resulted in a 55% increase in human sdLDL oxidation as compared to non-glucose-treated controls as measured by a marker of oxidation (malondialdehyde (MDA)). EPA inhibited this glucose-induced sdLDL oxidation in a dose-dependent fashion and, at the highest concentration tested (10.0 µM), EPA inhibited sdLDL oxidation by 94% compared to vehicle treated (ethanol) control.
Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body.
This poster was presented by Dr. R. Preston Mason, PhD, of Brigham and Women's Hospital. Dr. Mason is also the President and Founder of Elucida Research.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. For more information about Amarin visit www.amarincorp.com.
Forward-looking statements
This press release contains forward-looking statements, including statements about the potential efficacy, safety and therapeutic benefits of EPA, including statements about the potential clinical importance of the findings presented. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with in vitro research, research and development and clinical trials, including the risk that in vitro study results may not be predictive of future results or replicated in study in man and that studied parameters may not have clinically meaningful effect. A list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Investor RelationsMichael Farrell Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) [email protected] Morrell Trout Group In U.S.: +1 (646) [email protected] InquiriesLee Davies Makovsky In U.S.: +1 (212) [email protected]
Source: Amarin Corp. Plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keurig Dr Pepper Inc. (KDP) Confirms Previously Announced Resignation of CEO Gamgort, Appoints Timothy Cofer New CEO
- Cue Health Inc. (HLTH) Announces CFO Resignation
- HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!